Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 3.13 MB
Add to list
  1. Search results
  2. Overcoming challenges in co-formulati...

Overcoming challenges in co-formulation of proteins with contradicting stability profiles: EPO plus G-CSF

Dennis Krieg, Hristo Svilenov (UGent) , Julian H. Gitter and Gerhard Winter
(2020) EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 141.
Author
Organization
Abstract
The co-formulation of drugs is widely used for small molecules, e.g. fixed-dose-combinations of synergistic medicines in the treatment of infections, diabetes or neurodegenerative diseases. For protein drugs, only a few studies have been published to elucidate the challenges of stabilizing two proteins in one formulation. Here, we show a systematic study with the model proteins EPO and G-CSF, which differ significantly in their physicochemical properties. We apply several analytical methods to investigate the stability of the co-formulated proteins in the liquid and solid state. Forced degradation studies at elevated temperature indicate poor stability of the liquid co-formulations. Therefore, we use lyophilization as a stabilization strategy. Finally, we adopt an elegant approach, in which the proteins are lyophilized at pH 4.0 and reconstituted with buffer at pH 7.0 to obtain high monomer recovery and to preserve the protein structure of both EPO and G-CSF. After reconstitution, both proteins in co-formulation remain stable for the timespan until eventual application in patients. With this case study, we demonstrate how to overcome some challenges during the co-formulation of therapeutic proteins.
Keywords
Pharmaceutical Science, Protein stability, Protein formulation, Protein aggregation, Therapeutic proteins, Lyophilization, COLONY-STIMULATING FACTOR, RECONSTITUTION MEDIUM, AGGREGATION RATES, IN-VIVO, ERYTHROPOIETIN, INTERLEUKIN-2, MOBILIZATION

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 3.13 MB

Citation

Please use this url to cite or link to this publication:

MLA
Krieg, Dennis, et al. “Overcoming Challenges in Co-Formulation of Proteins with Contradicting Stability Profiles: EPO plus G-CSF.” EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 141, 2020, doi:10.1016/j.ejps.2019.105073.
APA
Krieg, D., Svilenov, H., Gitter, J. H., & Winter, G. (2020). Overcoming challenges in co-formulation of proteins with contradicting stability profiles: EPO plus G-CSF. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 141. https://doi.org/10.1016/j.ejps.2019.105073
Chicago author-date
Krieg, Dennis, Hristo Svilenov, Julian H. Gitter, and Gerhard Winter. 2020. “Overcoming Challenges in Co-Formulation of Proteins with Contradicting Stability Profiles: EPO plus G-CSF.” EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 141. https://doi.org/10.1016/j.ejps.2019.105073.
Chicago author-date (all authors)
Krieg, Dennis, Hristo Svilenov, Julian H. Gitter, and Gerhard Winter. 2020. “Overcoming Challenges in Co-Formulation of Proteins with Contradicting Stability Profiles: EPO plus G-CSF.” EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 141. doi:10.1016/j.ejps.2019.105073.
Vancouver
1.
Krieg D, Svilenov H, Gitter JH, Winter G. Overcoming challenges in co-formulation of proteins with contradicting stability profiles: EPO plus G-CSF. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2020;141.
IEEE
[1]
D. Krieg, H. Svilenov, J. H. Gitter, and G. Winter, “Overcoming challenges in co-formulation of proteins with contradicting stability profiles: EPO plus G-CSF,” EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 141, 2020.
@article{8741207,
  abstract     = {{The co-formulation of drugs is widely used for small molecules, e.g. fixed-dose-combinations of synergistic medicines in the treatment of infections, diabetes or neurodegenerative diseases. For protein drugs, only a few studies have been published to elucidate the challenges of stabilizing two proteins in one formulation. Here, we show a systematic study with the model proteins EPO and G-CSF, which differ significantly in their physicochemical properties. We apply several analytical methods to investigate the stability of the co-formulated proteins in the liquid and solid state. Forced degradation studies at elevated temperature indicate poor stability of the liquid co-formulations. Therefore, we use lyophilization as a stabilization strategy. Finally, we adopt an elegant approach, in which the proteins are lyophilized at pH 4.0 and reconstituted with buffer at pH 7.0 to obtain high monomer recovery and to preserve the protein structure of both EPO and G-CSF. After reconstitution, both proteins in co-formulation remain stable for the timespan until eventual application in patients. With this case study, we demonstrate how to overcome some challenges during the co-formulation of therapeutic proteins.}},
  articleno    = {{105073}},
  author       = {{Krieg, Dennis and Svilenov, Hristo and Gitter, Julian H. and Winter, Gerhard}},
  issn         = {{0928-0987}},
  journal      = {{EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES}},
  keywords     = {{Pharmaceutical Science,Protein stability,Protein formulation,Protein aggregation,Therapeutic proteins,Lyophilization,COLONY-STIMULATING FACTOR,RECONSTITUTION MEDIUM,AGGREGATION RATES,IN-VIVO,ERYTHROPOIETIN,INTERLEUKIN-2,MOBILIZATION}},
  language     = {{eng}},
  pages        = {{10}},
  title        = {{Overcoming challenges in co-formulation of proteins with contradicting stability profiles: EPO plus G-CSF}},
  url          = {{http://doi.org/10.1016/j.ejps.2019.105073}},
  volume       = {{141}},
  year         = {{2020}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: